Number (%) | |
---|---|
Median Age, years | 52.5 |
ECOG performance status | |
0 | 4 (8.9) |
1 | 36 (80.0) |
2 | 5 (11.1) |
Initial stage at diagnosis | |
I | 6 (14.6) |
II | 20 (38.8) |
III | 6 (14.7) |
IV | 9 (22.0) |
Metastatic site | |
Locally advanced | 4 (8.9) |
Regional lymph nodes | 7 (15.6) |
Distant lymph nodes | 14 (31.1) |
Lung | 18 (40.0) |
Liver | 17 (37.8) |
Bone | 25 (55.6) |
Skin/Soft tissue | 8 (17.8) |
Others | 13 (28.9) |
Number of metastatic sites | |
0-1 | 9 (20.00) |
2 | 11 (24.44) |
≥3 | 25 (55.56) |
Previous anthracycline | |
Yes | 7 (16.28) |
No | 36 (83.72) |
Estrogen receptor | |
Positive | 26 (57.78) |
Negative | 16 (35.56) |
Unknown | 3 (6.67) |
Her-2 expressiona | |
0, 1+ | 30 (66.67) |
2+ | 4 (8.89) |
3+ | 5 (11.11) |
Unknown | 6 (13.33) |